Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

GIST pipeline

Trial arms side by side.

One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.

ClassNone selected

No arms selected. Choose a drug, an arm, or a preset.

Each arm uses its closest stored timepoint inside the window.

Cross-trial values

value

Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.

No selected arm has this endpoint inside the time window.

Show as table
ArmTrialPhasePopulationnComparatorTimepointEstimandAssessorValue

Not shown

Every selected arm is drawn.

26 of 32 arms with a reported figure. Choose arms to narrow the chart.

Drug, trialPopulationDoseEstimandComparatorORR, %mPFS, monthsmOS, monthsHazard ratioOther
Imatinib 400 mgImatinib Phase 3 dose trials (combined analysis on label)unresectable or metastatic KIT (CD117) positive GIST400 mgITTn/rbest overall response (complete 5.3% plus partial 46.1%): 51.4%, combined analysis, Sum of label complete response 43 (5.3%) and partial response 377 (46.1%)median progression-free survival: 18.9 months, median follow up 37.5 monthsmedian overall survival: 49 months, median follow up 37.5 monthsn/rn/r
Imatinib 800 mgImatinib Phase 3 dose trials (combined analysis on label)unresectable or metastatic KIT (CD117) positive GIST800 mgITTimatinib 400 mgn/rmedian progression-free survival: 23.2 months, median follow up 37.5 monthsmedian overall survival: 48.7 months, median follow up 37.5 monthsn/rn/r
Imatinib 400 mgImatinib Phase 2 (400 vs 600 mg)KIT (CD117) positive unresectable or metastatic GIST400 mgITTimatinib 600 mgobjective response rate (SWOG): 68.5%, up to 36 monthsn/rn/rn/rn/r
Imatinib 600 mgImatinib Phase 2 (400 vs 600 mg)KIT (CD117) positive unresectable or metastatic GIST600 mgITTimatinib 400 mgobjective response rate (SWOG): 67.6%, up to 36 monthsn/rn/rn/rn/r
Imatinib 400 mgAdjuvant Study 1 (ACOSOG Z9001)resected primary GIST 3 cm or more400 mgITTplacebon/rn/rn/rrecurrence-free survival hazard ratio vs placebo (interim): 0.4 HR, median follow up 15 monthsrecurrence-free survival hazard ratio vs placebo (updated): 0.72 HR, median follow up 50 monthsn/r
Imatinib 400 mgAdjuvant Study 2 (SSG XVIII)resected high-risk KIT positive GIST400 mgITTimatinib for 12 monthsn/rn/rn/rrecurrence-free survival hazard ratio, 36 vs 12 months: 0.46 HR, median follow up 42 monthsoverall survival hazard ratio, 36 vs 12 months: 0.45 HR, median follow up 48 monthsn/r
Sunitinib 50 mgStudy 1GIST after imatinib progression or intolerance50 mgITTplaceboobjective response rate (partial responses): 6.8%, interim analysismedian time to tumor progression: 27.3 weeks, interim analysismedian progression-free survival: 24.1 weeks, interim analysisn/rn/rn/r
Sunitinib placeboStudy 1GIST after imatinib progression or intoleranceplaceboITTThis arm is placebon/rmedian time to tumor progression: 6.4 weeks, interim analysismedian progression-free survival: 6 weeks, interim analysisn/rn/rn/r
Regorafenib 160 mgGRIDGIST after imatinib and sunitinib160 mgITTplacebon/rmedian progression-free survival: 4.8 months, primary analysismedian overall survival: 17.4 months, final OS analysis, 162 eventsprogression-free survival hazard ratio vs placebo: 0.27 HR, primary analysisn/r
Regorafenib placeboGRIDGIST after imatinib and sunitinibplaceboITTThis arm is placebon/rmedian progression-free survival: 0.9 months, primary analysismedian overall survival: 17.4 months, final OS analysis; 88% crossed overn/rn/r
Ripretinib 150 mgINVICTUSGIST after imatinib, sunitinib and regorafenib150 mgITTplaceboobjective response rate (BICR): 9%, primary analysismedian progression-free survival (BICR): 6.3 months, primary analysismedian overall survival: 15.1 months, not tested for significanceprogression-free survival hazard ratio vs placebo: 0.15 HR, primary analysisn/r
Ripretinib placeboINVICTUSGIST after imatinib, sunitinib and regorafenibplaceboITTThis arm is placebon/rmedian progression-free survival (BICR): 1 months, primary analysismedian overall survival: 6.6 months, 66% switched to ripretinibn/rn/r
Ripretinib 150 mgINTRIGUEGIST after imatinib (ITT n = 226)150 mgITTsunitinib 50 mg 4/2objective response rate, KIT exon 11 ITT: 23.9%, primary analysis; nominal P = .03median progression-free survival (IRR), ITT: 8 months, primary analysismedian progression-free survival, KIT exon 11 ITT: 8.3 months, primary analysismedian PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 14.2 months, exploratory, Exploratory ctDNA analysis (Heinrich, Nat Med 2024); nominal Pn/rprogression-free survival hazard ratio vs sunitinib, ITT: 1.05 HR, primary analysis; not significantn/r
Ripretinib 50 mgINTRIGUEGIST after imatinib (ITT n = 227)50 mgITTn/robjective response rate, KIT exon 11 ITT: 14.6%, primary analysismedian progression-free survival (IRR), ITT: 8.3 months, primary analysismedian progression-free survival, KIT exon 11 ITT: 7 months, primary analysismedian PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 1.5 months, exploratorymedian PFS, exploratory ctDNA KIT exon 11 + 13/14 (sunitinib vs ripretinib 4.0): 15 months, exploratoryn/rn/rn/r
Avapritinib 300 or 400 mgNAVIGATORunresectable or metastatic GIST with PDGFRA exon 18 mutation (n = 43)300 or 400 mgSingle armn/roverall response rate (independent review): 84%, median follow up 10.6 monthsn/rn/rn/rn/r
Avapritinib 300 or 400 mgNAVIGATORPDGFRA D842V (n = 38)300 or 400 mgSingle armn/roverall response rate (independent review): 89%, median follow up 10.6 monthsn/rn/rn/rn/r
Avapritinib 300 or 400 mgNAVIGATORGIST, 267 patients in intracranial hemorrhage pooled count300 or 400 mgSingle armn/rn/rn/rn/rn/rn/r
Avapritinib 300 mgVOYAGER3L or later GIST (n = 240)300 mgITTregorafenib 160 mgobjective response rate: 17.1%, primary analysismedian progression-free survival: 4.2 months, primary analysisn/rprogression-free survival hazard ratio vs regorafenib: 1.25 HR, primary analysis; P = .055n/r
Avapritinib 160 mgVOYAGER3L or later GIST (n = 236)160 mgITTn/robjective response rate: 7.2%, primary analysismedian progression-free survival: 5.6 months, primary analysisn/rn/rn/r
Bezuclastinib + Sunitinib 600 mg + 37.5 mgPeakGIST after imatinib (n = 204)600 mg + 37.5 mgITTsunitinib 37.5 mgobjective response rate (BICR): 46%, data cutoff 09.30.2025median progression-free survival (BICR): 16.5 months, data cutoff 09.30.2025n/rprogression-free survival hazard ratio vs sunitinib: 0.5 HR, data cutoff 09.30.2025PFS2 hazard ratio vs sunitinib: 0.57 HR, ASCO 2026 updaten/r
Bezuclastinib + Sunitinib 37.5 mgPeakGIST after imatinib (n = 209)37.5 mgITTn/robjective response rate (BICR): 26%, data cutoff 09.30.2025median progression-free survival (BICR): 9.2 months, data cutoff 09.30.2025n/rn/rn/r
Velzatinib (IDRX-42, GSK6042981) 300 mgStrateGIST 12L advanced GIST (n = 46)300 mgSingle armn/robjective response rate: 35%, cutoff 12.15.2025median progression-free survival: 13.7 months, median follow up 14.7 months; cutoff 12.15.2025n/rn/rn/r
Velzatinib (IDRX-42, GSK6042981) 300 mgStrateGIST 11L advanced GIST (n = 18)300 mgSingle armn/runconfirmed objective response rate: 61%, median follow up 6.4 monthsn/rn/rn/rn/r
Olverembatinib (HQP1351) 30 to 50 mgHQP1351SJ0003SDH-deficient GIST (n = 26)30 to 50 mgSingle armn/rpartial response as best response: 23.1%, cutoff 11.13.2025median progression-free survival: 25.7 months, cutoff 11.13.2025n/rn/rn/r
NB003 not stated in sourceNB003 Phase 1GIST 2L to 4L or later (n = 158)not stated in sourceSingle armn/robjective response rate: 28.5%, data as of March 2025median progression-free survival: 9.2 months, data as of March 2025n/rn/rn/r
NB003 not stated in sourceNB003 Phase 1GIST 3L (n not stated in source)not stated in sourceSingle armn/robjective response rate: 46.7%, data as of March 2025median progression-free survival: 13.7 months, data as of March 2025n/rn/rn/r

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.